OmniAb, Inc.
OABIHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeOmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United. At a $378.4M market cap, OmniAb, Inc. ranks as a small-cap company within healthcare. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Market Cap
$378.4M
Beta
0.62
P/E (TTM)
—
P/E (Fwd)
-8.09
EPS (TTM)
$-0.46
EPS (Fwd)
$-0.32
ROE
-20.3%
ROA
-11.3%
Cash
$49.1M
Total Debt
$19.7M
Free CF
-$2.6M
52W Change
90.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $49.1M in cash comfortably exceeding the $19.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$2.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -20.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $59.1M (2022) to $18.7M (2025), a 68% decline worth watching.
With a beta below 0.7, OmniAb, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing OABI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.